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Abstract
Background: Placebo effects and their underpinning mechanisms are increasingly well understood. However, this is poorly
communicated to participants in placebo-controlled trials. For valid informed consent, participants should be informed about the
potential benefits and risks of participating in placebo-controlled trials. Existing information leaflets often fail to describe the
potential benefits and adverse effects associated with placebo allocation. This study tested the effects of a new website designed
to inform patients about placebo effects (The Power of Placebos, PoP). PoP was designed using qualitative methods in combination
with theory- and evidence-based approaches to ensure it was engaging, informative, and addressed patients’ concerns.
Objective: This study aimed to test the effects of PoP, compared with a control website, on people’s knowledge about placebo
and the ability to make an informed choice about taking part in a placebo-controlled trial.
Methods: A total of 350 adults with back pain recruited from 26 general practices in Southern England participated in this
Web-based study. Participants were randomly assigned to PoP (which presented scientifically accurate information about placebo
effects in an engaging way) or a control website (based on existing information leaflets from UK trials). Participants self-completed
Web-based pre- and postintervention questionnaire measures of knowledge about placebo effects and preintervention questionnaire
measures of attitudes toward and intentions to participate in a placebo-controlled trial. The 2 primary outcomes were (1) knowledge
and (2) informed choice to take part in a placebo-controlled trial (computed from knowledge, attitudes, and intentions).
Results: After viewing PoP, participants had significantly greater knowledge about placebos (mean 8.28 [SD 1.76]; n=158)
than participants who viewed the control (mean 5.60 [SD 2.24]; n=174; F1,329=173.821; P<.001; η
2=.346). Participants who
viewed PoP were 3.16 times more likely than those who viewed the control to make an informed choice about placebos (χ21=36.5;
P<.001).
Conclusions: In a sample of adults with back pain, PoP increased knowledge and rates of informed choice about placebos
compared with a control website. PoP could be used to improve knowledge about placebo effects in back pain. After essential
further development and testing in clinical trial settings, it could support informed consent in placebo-controlled trials.
J Med Internet Res 2019 | vol. 21 | iss. 1 | e9955 | p.1https://www.jmir.org/2019/1/e9955/
(page number not for citation purposes)
Bishop et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
(J Med Internet Res 2019;21(1):e9955)   doi:10.2196/jmir.9955
KEYWORDS
placebos; placebo effects; informed consent; research ethics; health knowledge, attitudes, practice; internet
Introduction
Background
Placebo-controlled trials remain the gold standard for
establishing the efficacy of new pharmacological and other
interventions and are often used in pain medicine. According
to the Declaration of Helsinki, investigators should obtain a
priori voluntary informed consent from participants after
informing them about “the anticipated benefits and potential
risks of the study and the discomfort it may entail” (item 26,
[1]). Although participant information leaflets typically focus
on the benefits and risks of the new intervention being trialed
[2], placebos themselves can trigger both beneficial and adverse
effects in a range of conditions, particularly pain [3-7]. Patients
in a trial who receive the placebo may thus experience placebo
and/or nocebo effects but are unlikely to have been informed
about them in advance. Arguably, it should be standard practice
to inform patients in placebo-controlled trials about the placebo
and its possible benefits and adverse effects [8].
Current information provision about placebo interventions in
clinical trials is likely to be inadequate and thus jeopardizes the
validity of informed consent. Qualitative studies and surveys
suggest that members of the public and trial participants often
have misunderstandings and partial knowledge about placebos
and their effects [9,10]. For example, trial participants often
believe that placebo effects are fake or illusory and that people
who respond to placebos are gullible or foolish [10-12]. Such
beliefs are inconsistent with the scientific literature on placebo
effects and may: deter people from volunteering for trials [13];
contribute to patient anxiety about placebo effects [11]; and/or
make it difficult for participants to make sense of a personal
placebo response when debriefed to placebo allocation at the
end of a trial [14,15]. Furthermore, only a small minority of
people understand that placebos can have adverse effects; this
has been found consistently across surveys of trial participants
[9] and patients [16-18]. These beliefs are also unlikely to be
challenged by existing patient information leaflets, which barely
mention the placebo; a content analysis of participant
information leaflets from major UK-based placebo-controlled
trials found that only 1 of the 45 leaflets studied explicitly stated
that patients might experience beneficial effects from the
placebo, only 4 leaflets explicitly stated that patients might
experience adverse effects from the placebo, and 8 leaflets
explicitly stated that the placebo treatment was either undesirable
or ineffective [2]. This paucity of information about placebos
is probably widespread, as studies of patient information leaflets
have reported similar findings, for example, in Finland [19],
Spain [20], and internationally [21].
Preliminary evidence suggests it is possible to improve people’s
understandings of placebos [22,23], but effects in well-defined
clinical populations and on key outcomes such as informed
choice have not been evaluated. Web-based resources could
usefully augment or improve existing paper-based information
leaflet because websites (1) are increasingly popular with health
consumers [24,25]; (2) easily incorporate interactive features
[26], which can enhance engagement and effective education
[27]; (3) are easily and cheaply disseminated for widespread
access [26]; and (4) can be readily adapted and/or tailored for
use in different clinical trials [26].
Objectives
A Web-based experiment was conducted to compare a newly
developed, scientifically accurate, and engaging website about
placebos—The Power of Placebos (PoP) [28]—with a control
website based on existing patient information about placebos.
PoP was designed for and tested in adults with back pain because
placebo analgesia is well documented in this population
[3,5,29,30]. It was important to focus on 1 condition as the
nature of and mechanisms underpinning placebo effects differ
by disease [31]. Back pain is a major public health concern [32]
as it is the leading cause of disability in most countries [33].
The most effective therapies appear to involve exercise and
education [34], although 1 study has found improvements in
back pain after open-label placebo treatment [35]. The
hypotheses were that PoP would increase knowledge about
placebos, enable more patients to make an informed choice
about having placebos, and encourage people to believe that
placebos can have credible analgesic and adverse effects.
Methods
Design
This Web-based study tested the effects of a newly developed
interactive website (PoP) on patients’ knowledge, informed
choice, and beliefs about placebos. Participants were randomized
automatically by the overarching study website to view either
PoP or the control website. They also saw a separate website
about acupuncture (again either a newly developed one or a
control), as this study was part of a larger 2 × 2 factorial trial
(for details, see Multimedia Appendix 1). As there were no
effects of the acupuncture website manipulation on patients’
knowledge, informed choice, and beliefs about placebos, this
study reports the PoP versus control comparison for the placebo
website only. The equivalent comparison for the acupuncture
website is being reported separately.
Furthermore, 2 volunteers, with personal experience of back
pain and clinical research, acted as patient advisors in this study.
Research has shown that such “patient public involvement” in
research can enhance the design and conduct of studies [36].
Both our volunteers participated in team meetings, which
involved discussions and decision making around study design,
procedures, and conduct. The patient advisors also helped to
finalize recruitment materials and contributed to website design,
for example, by providing feedback on prototypes of PoP. Of
the 2 advisors, 1 advisor also chose to contribute to the process
of writing up for publication.
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Ethical approval was sought and obtained from the University
of Southampton (Ethics ID: 12323) and the NHS NRES
(National Health Service National Research Ethics Service)
Committee East of England-Hatfield (Research Ethics
Committee reference: 14/EE/1176).
Participants and Recruitment
Adults aged 18 years and older with a recent history of back
pain (within 3 years) as documented by their general practitioner
(GP) were recruited via 26 general practices in South West
England between December 2014 and March 2015. General
practice staff conducted database searches and mailed study
invitation packs to eligible patients. Invitation packs contained
a cover letter and information sheet including the study website
address. Participants needed to be computer literate to self-enroll
in the study and complete it independently (technical support
was available from the researchers by telephone or email if
needed). People with needle phobia (important for the
acupuncture websites) or unable to complete questionnaires in
English were excluded. Figure 1 shows the flow of participants
through the study.
An a priori power calculation was conducted using G*Power
(Heinrich Heine Universitat Dusseldorf) [37]. Assuming an
effect size f=0.15 (based on unpublished pilot data), power 0.8,
and alpha .05 for a factorial analysis of variance (ANOVA)
required a total of 351 participants, and assuming 5% dropout
required 369 patients to be randomized.
Interventions
Overall, 2 websites about placebo effects were developed for
this study: a person-based website and a control website. Both
websites were explicitly labeled as developed at the University
of Southampton and included identical brief biographies of the
research team. Participants were not told which website they
were viewing. Both websites presented information about
placebo effects and were created using LifeGuide software, a
package developed for researchers to design, build, and trial
Web-based interventions [38]. Guidance for developing
patient-focused health information was followed to ensure both
websites were understandable, readable, and accessible [39].
The person-based website was longer than the control website
(10 pages vs 5 pages). Table 1 compares the content and formats
of each website. No changes to the websites were made during
this study.
Figure 1. Flow of participants through the study. GP: general practitioner; PoP: The Power of Placebos.
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Table 1. Summary comparison of The Power of Placebos (PoP) and control websites.
ControlPoPContent and format of websites
Contents
✓✓aDefining placebos 
✓✓Potential benefits of placebo 
Xb✓Potential adverse effects of placebo 
X✓Patients’ experiences of placebos 
X✓Common concerns about placebos 
X✓Debunking myths that placebo responders are malingerers or gullible 
X✓Mechanisms underpinning placebo effects 
✓✓Placebos in placebo-controlled trials 
X✓Placebos in clinical practice 
Formats
✓✓Text 
✓✓Images 
X✓Film 
X✓Audio clips 
aTick indicates feature is present in the website.
bCross indicates feature is absent in the website.
The Power of Placebos Website
PoP was developed using a rigorous approach derived from
person-based intervention development, which incorporates
evidence and theory [40-42]. This entailed extensive intervention
planning, drawing on existing evidence and theory about placebo
effects and how to change patients’ health beliefs and behaviors,
and conducting qualitative think-aloud interviews to develop
and refine the website. The content was based on published
scientific evidence [3,4,31,43] and targeted theoretically
informed constructs (primarily knowledge but also attitudes,
subjective norms, and perceived behavioral control, derived
from the Theory of Planned Behavior [44]). For a full
description of the development process and the resulting website,
refer to the study by Greville-Harris et al [28]. Figure 2 shows
an example page, and screenshots showing additional pages are
available in Multimedia Appendix 2. A completed TIDieR
(template for intervention description and replication) checklist
in Multimedia Appendix 3 presents full information about the
description of PoP.
The Control
The control website was based on the limited information about
placebos that is included in some UK patient information leaflets
for placebo-controlled clinical trials. Consistent with common
practice among those leaflets that provide any information about
placebos [2], it provided only minimal detail about the possible
effects of placebos and did not explain their mechanisms of
action. Figure 3 shows an example page. Screenshots of the
entire control website are available in Multimedia Appendix 4.
Measures
Participants’ Characteristics
Items selected from the recommended minimum dataset for
back pain [45] were used to assess clinical characteristics (pain
duration, pain frequency, pain intensity, pain catastrophizing,
and pain spread to legs), pain-related legal claims, disability
benefits or compensation (all single items), and pain functioning
and interference (4-item scales with excellent internal
consistency in this sample; Cronbach alphas .96 and .92,
respectively). Single items assessed ethnicity, age, gender, and
education level.
Primary Outcomes
Primary outcomes were knowledge and informed choice about
placebos. Informed choice was selected as an analogy to
informed consent because the website was being tested outside
the context of a placebo-controlled trial. Informed choice is a
composite measure based on knowledge, attitudes, and intentions
to try placebo, the components of which were measured after
participants had finished viewing the website.
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Figure 2. Screenshot from the Power of Placebos website: How do placebos work?
Figure 3. Screenshot from control webpage.
Placebo knowledge was assessed using a 10-item knowledge
quiz, comprising true-false questions developed and validated
in preparation for this study. These 10 items were selected from
a larger pool of 15 items pilot tested in a Web-based study with
a community-based sample of 210 adults with a history of back
pain [18]. The 10 items most commonly answered incorrectly
by the community-based sample were chosen for this study (eg,
“A placebo pill can have side effects” and “Placebo pills can
help to treat pain conditions”—both are true). The knowledge
score is the total number of items answered correctly. The quiz
was completed before and after viewing the websites. The pre-
and postadministrations had acceptable internal consistency in
this sample (Cronbach alphas .66 and .79, respectively).
Making an informed choice can be understood as choosing to
act in a way that is based on one’s knowledge and one’s values
[46-48]. To make an informed choice, a person needs to have
an accurate understanding of the options available, have formed
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an opinion about the options based on their personal values, and
make a decision (or otherwise act in a way) that is consistent
with their knowledge and values [46-48]. Although it can be
argued that knowledge alone is sufficient for informed choice,
attitudes are incorporated in our chosen definition as an attempt
to reflect the role of personal values in making health decisions
that are optimized for the individual concerned. If decisions
were based on knowledge alone, people could still make
decisions that are inconsistent with their personal values and so
could be considered sub-optimal for them as individuals. By
choosing a definition of informed choice that incorporates
attitudes, we are better able to model the role of personal values
in decision making. From this perspective, an informed choice
to have a placebo requires knowledge about the possible
beneficial and adverse effects of placebos, a positive attitude to
placebos, and a decision to try a placebo. An informed choice
not to have a placebo requires knowledge about the possible
beneficial and adverse effects of placebos, a negative attitude
to placebos, and a decision not to try a placebo.
In this study, knowledge was measured using the placebo
knowledge quiz. Attitudes were measured using 4 items derived
following the Theory of Planned Behavior guidelines for
measuring attitudes [49], for example, “having a placebo
treatment would be good.” Behavioral intentions were used as
a proxy for behavior and were measured using 3 items derived
following the same guidelines [49], for example, “if given the
opportunity, I intend to have a placebo treatment.” Items
assessing attitudes and intentions were measured on 7-point
Likert-type scales labeled strongly disagree to strongly agree,
and scores across constituent items were averaged. The scales
had good internal consistency (Cronbach alphas .97 and .87,
respectively).
Participants were categorized as making an informed choice or
not based on their attitude (split by scale midpoint to produce
2 groups with positive and negative attitudes), intention to have
treatment (split by scale midpoint to produce 2 groups with
positive and negative intentions), and their knowledge score
(based on median split to produce 2 groups with high and low
knowledge). Participants were categorized as making an
informed choice if they scored above the median on knowledge
and either (a) above the scale midpoint on both attitudes and
intentions or (b) below the scale midpoint on both attitudes and
intentions. All other participants were categorized as not making
an informed choice. Although there are drawbacks of computing
composite measures in this way (see Discussion), this approach
enabled us to follow published definitions of informed choice
to create a primary outcome measure with good face validity
and is consistent with previous studies of informed choice in
other settings [46-48].
Secondary Outcomes
Secondary outcomes were participants’ beliefs about placebos
and willingness to try a placebo. These were completed after
participants had finished viewing the website.
Overall, 4 dimensions of beliefs about placebos were measured
using the previously validated 4-item subscales of the Low Back
Pain Treatment Beliefs Questionnaire [50]: concerns (eg, “I
have concerns about having placebos for my back pain”),
individual fit (eg, “I am confident placebos would be a suitable
treatment for my back pain”), expectancy (eg, “Placebos can
work well for people with back pain”), and credibility (eg,
“Generally, placebos are a believable therapy for back pain”).
The Low Back Pain Treatment Beliefs Questionnaire was
validated in a Web-based study [50]. All items used 5-point
Likert-type response scales labeled strongly disagree to strongly
agree. All subscales had good internal consistency in this sample
(Cronbach alpha for concerns=.72, individual fit=.91,
expectancy=.94, and credibility=.84).
A single yes or no item asked whether participants would be
“willing to have placebo treatment.” As participants could take
breaks from viewing the website and return later, an item was
also included to assess whether participants had “looked up
additional information about placebo during breaks from the
study.”
Procedure
On accessing the study website at a time and location of their
choice (eg, at home), not in the presence of a researcher,
participants viewed the information sheet and indicated consent
to take part by clicking a button (see Multimedia Appendix 5
for information sheet). Participants were then asked 3 mandatory
screening questions assessing age, current or recent back pain,
and needle phobia. Those not meeting the associated inclusion
criteria were directed to an exit page. Those passing the
screening questions entered their email address and created a
password for the website, which allowed participants to take
breaks when desired. Participants then completed the 10-item
placebo knowledge quiz to assess baseline knowledge before
being presented with the series of 2 websites (placebo and
acupuncture) appropriate to their randomization group.
Participants could take breaks, log out and return to the study
later, and stop viewing each website whenever they wanted
(“click here when you have finished looking at the information”
was available on every page). Directly after viewing the
websites, participants completed the primary and secondary
outcome measures and measures of sociodemographic and
clinical characteristics. All measures were completed on the
study website. Finally, participants were directed to a debriefing
page with further information about the study and links to other
resources. Everyone who completed the study was emailed a
£10 online shopping voucher.
Statistical Analysis
Data were downloaded from LifeGuide and imported into IBM
SPSS Statistics v22 for analysis. The proportion of missing data
was small (<5% on any 1 variable) but was not missing
completely at random (MCAR; Little MCAR test: χ27845=8279.7;
P<.001), suggesting imputation might be inappropriate but
unlikely to alter the results [51]. All analyses were repeated
excluding missing data and then imputing missing values with
the expectation-maximization algorithm. The results were the
same, and the reported analyses used all available data with no
imputation.
Pearson’s chi-square test compared the proportions of people
(a) making an informed choice and (b) willing to have a placebo,
between PoP and the control website. ANOVAs tested the
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effects of PoP compared with control on postintervention
measures of knowledge and treatment perceptions. Analyses of
covariance were then computed adjusting for baseline
knowledge [52], which was the only baseline variable to differ
between the groups.
Results
Participants’ Characteristics
The final sample comprised 350 adults, of whom the majority
were female, white British, and educated up to at least 18 years
(see Table 2). The average age of participants was 47.88 years
(SD 15.8; control group mean age 48.80 years [SD 15.9]; PoP
group mean age 46.88 years [SD 15.6]). Almost all participants
(308/350, 88.0%) reported having back pain in the last week,
and on average, they reported pain interfering with daily
activities between a little bit and somewhat and being able to
perform functional tasks such as chores or walking with a little
difficulty. Participants’ back pain was typically longstanding
(157/350, 45.1% had onset over 5 years ago), affected them
daily or almost daily (133/350, 38.0%), and was of moderate
intensity (mean 4.75 on a 10-point scale; control group mean
4.79 [SD 2.46]; PoP group mean 4.71 [SD 2.40]). Pain
interference in the past week was also moderate (control group
mean 2.58 [SD 1.29]; PoP group mean 2.58 [SD 1.25]; on a
5-point scale) as was current pain functioning (control group
mean 1.98 [SD 0.96]; PoP group mean 2.06 [SD 1.02]; on a
5-point scale). Approximately, one-third (126/350, 36.0%)
reported pain catastrophizing. Very few participants (2 per
group) reported looking up additional information about placebo
effects during the study. The groups did not differ significantly
on any of these measures (all P values >.05), except baseline
knowledge about placebo, on which the PoP group scored
slightly higher (mean 6.21 [SD 2.14]) than the control group
(mean 5.72 [SD 2.20]; t340=−2.08; P=.04).
Knowledge, Attitudes, and Intentions
There was a significant main effect of website on placebo
knowledge: after viewing the website, people who viewed PoP
had higher knowledge about placebo effects than people who
viewed the control website (Table 3). On average, people who
viewed PoP also had less positive attitudes and more positive
intentions toward placebo effects than people who viewed the
control website, but these effects were much smaller than the
effect on knowledge (Table 3).
Informed Choice
Table 4 shows how participants were classified as making an
informed choice or not according to their knowledge, attitudes,
and intentions. There was a significant association between
website and informed choice about placebo (χ21=36.5; P<.001).
Almost half of people (66/146, 45.2%) who viewed PoP made
an informed choice about placebos compared with 14.3%
(24/168) of people who viewed the control website. Thus, people
who viewed PoP were 3.16 times more likely than those who
viewed the control website to make an informed choice about
placebos. The most common pattern of scores on components
of informed choice was to have negative intentions of having
placebos, and negative attitudes toward placebos, and low
knowledge about placebos, a pattern displayed by 27.4% of all
participants, 41.1% of participants who viewed the control
website, and 11.6% of participants who viewed PoP.
Treatment Beliefs
After viewing the website, people who viewed PoP had
significantly more positive beliefs that placebo treatment was
a good fit for them, had significantly higher expectations of
benefit from placebo, and perceived placebo treatment as
significantly more credible than people who viewed the control
website (Table 5). Level of concerns about placebo treatment
did not differ between the groups.
Willingness to Try Placebo
There was a significant effect of website on willingness to try
a placebo (χ21=10.1; P=.001). More than half of participants
(59.3%, 99/167) who had viewed PoP compared to 42.2%
(76/180) of those who had viewed the control website said they
would be willing to try a placebo. Thus, people who viewed
PoP were 1.41 times more likely than those who viewed the
control website to be willing to try a placebo.
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Table 2. Participants’ characteristics by group.
Frequency, n (%)Characteristic and category
PoPa (n=168)Control website (n=182)Whole sample (N=350) 
Sociodemographic characteristics
Gender 
95 (56.5)102 (56.0)197 (56.3)Female  
Ethnicity 
145 (86.3)166 (91.2)311 (88.9)White British  
9 (5.4)7 (3.8)16 (4.6)White (any other) 
3 (1.8)1 (0.5)4 (1.2)Asian or Asian British 
2 (1.2)0 (0.0)2 (0.6)Mixed ethnicity 
0 (0.0)1 (0.5)2 (0.6)Black or black British 
Education 
6 (3.6)13 (7.1)19 (5.4)Did not complete secondary school  
41 (24.4)48 (26.4)89 (25.4)Secondary school 
45 (26.8)61 (33.5)106 (30.3)Sixth form or college (aged 16-18 years) 
55 (32.7)43 (23.6)98 (28.0)Undergraduate study 
19 (11.3)16 (8.8)35 (10.0)Postgraduate study 
Clinical characteristics
Time since pain onset 
42 (25.0)29 (15.9)71 (20.4)Up to 1 year  
48 (28.6)57 (31.3)105 (30.2)1 to 5 years 
74 (44.0)83 (45.6)157 (45.1)>5 years 
Pain frequency in past 6 months 
63 (37.5)70 (38.5)133 (38.0)Every day or nearly every day  
45 (26.8)40 (22.0)85 (24.3)More than half the days 
49 (29.2)53 (29.1)102 (29.1)Less than half the days 
9 (5.4)7 (3.8)16 (4.6)Disability or compensation benefits 
3 (1.8)1 (0.5)4 (1.1)Legal claim related to back 
69 (41.1)73 (40.1)142 (40.6)Pain spread to leg or legs in past 2 weeks 
60 (35.7)66 (36.3)126 (36.0)Pain catastrophizing 
2 (1.2)4 (2.2)6 (1.7)Previous participation in a placebo-controlled trial 
2 (1.2)2 (1.1)4 (1.1)Looked up additional information about placebos during the study 
aPoP: The Power of Placebos.
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Table 3. Postintervention knowledge, attitudes, and intentions toward placebos by group.
ηp
2
Comparison across websitesaThe Power of PlacebosControl websiteMeasure
 P valueF test (df)n (%)Mean (SD)n (%)Mean (SD) 
0.346<.001173.821 (1,329)158 (48)8.28 (1.76)174 (52)5.60 (2.24)Knowledgeb
0.046<.00115.779 (1,326)156 (47)3.24 (1.31)173 (53)3.89 (1.28)Attitudesc
0.039<.00113.264 (1,330)161 (48)3.34 (1.87)172 (52)2.58 (1.65)Intentionsc
aModels adjusted for baseline knowledge.
bPossible score range 0 to 10 (10=high knowledge).
cPossible score range 1 to 7 (7=positive attitudes or intentions).
Table 4. Informed choice categories.
PoPa (n=146), n (%)Control website
(n=168), n (%)
Whole sample
(N=314), n (%)
IntentionsAttitudeKnowledgeInformed choice
3 (2.1)25 (14.9)28 (8.9)NegativePositiveLowNo
3 (2.1)14 (8.3)17 (5.4)PositiveNegativeLowNo
9 (6.2)20 (11.9)29 (9.2)PositivePositiveLowNo
17 (11.6)69 (41.1)86 (27.4)NegativeNegativeLowNo
39 (26.7)11 (6.5)50 (15.9)NegativePositiveHighNo
9 (6.2)5 (3.0)14 (4.5)PositiveNegativeHighNo
43 (29.5)9 (5.4)52 (16.6)PositivePositiveHighYes
23 (15.8)15 (8.9)38 (12.1)NegativeNegativeHighYes
aPoP: The Power of Placebos.
Table 5. Postintervention treatment beliefs by group.
ηp
2
Comparison across websitesbPoPaControl websiteTreatment belief
 P valueF test (df)n (%)Mean (SD)n (%)Mean (SD) 
0.0020.370.810 (1,333)163 (49)2.29 (0.84)173 (51)2.40 (0.82)Concernsc
0.067<.00123.728 (1,328)159 (48)2.76 (1.03)172 (52)2.19 (0.91)Individual fitc
0.151<.00158.657 (1,330)161 (48)3.40 (0.88)172 (52)2.59 (1.00)Expectancyc
0.099<.00136.529 (1,332)162 (48)3.06 (0.91)173 (52)2.43 (0.90)Credibilityc
aPoP: The Power of Placebos.
bModels adjusted for baseline knowledge.
cPossible score range 1 to 5 (5=positive beliefs or fewer concerns about placebo).
Discussion
Principal Findings
This study tested the effects of a new person-based website
about placebo effects, PoP, on adults with recent back pain, by
comparing it with a control website based on existing written
UK patient information leaflets. Participants who viewed PoP
had greater increases in knowledge about placebos and were 3
times more likely to make an informed choice about placebos
compared with participants who viewed the control website.
On average, participants who viewed PoP answered 2 more
knowledge quiz items correctly (out of a total of 10 items).
Compared with the control website, PoP also led participants
to perceive placebos as more credible, more effective, and more
suitable for them personally and to be more willing to try a
placebo in the future.
Other studies have also successfully modified people’s beliefs
and/or knowledge about placebos. For example, 1 study [22]
compared a brief educational intervention comprising 5 slides
presenting information about placebo effects and their
mechanisms with a control intervention presenting information
about the epidemiology, costs, and risk factors for
musculoskeletal pain. Participants with chronic musculoskeletal
pain were randomly assigned to 1 of the 2 interventions. Those
who viewed the placebo educational intervention subsequently
reported feeling more knowledgeable about placebo analgesia,
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seeing placebos as more active, more effective, and more
acceptable in a range of hypothetical clinical scenarios [22].
Another study [23] compared 2 patient information leaflets
about placebo-controlled randomized trials, one based on
standard information and the other supplemented with additional
information about placebos, their effects, and mechanisms of
action. In an online randomized experiment, people with chronic
illness who viewed the supplemented leaflet subsequently
reported significantly higher expectations and perceptions of
the credibility of placebo treatment for pain compared with
those who viewed the standard information leaflet [23]. PoP is
more comprehensive than educational and/or informational
resources on placebo effects reported previously, and it was
developed using a systematic approach described in detail
elsewhere [28]. Similar to the studies by Kisaalita et al [22] and
Bishop et al [23], this study has shown that information about
placebos and placebo effects can lead patients to have more
positive beliefs about placebos. This study has also shown
effects on beliefs about placebos in a large sample of patients
with a particular pain condition. Uniquely, PoP had a significant
effect on objectively measured knowledge and informed choice,
a close analogy to informed consent in both clinical and research
settings. PoP also increased willingness to try a placebo,
suggesting it might help facilitate recruitment to
placebo-controlled randomized controlled trials (RCTs). Future
work should test PoP in the context of a placebo-controlled trial,
to ascertain whether it can indeed encourage more people to
volunteer.
PoP could be readily adapted for use in other conditions, which,
like pain, have well-documented placebo effects (such as
irritable bowel syndrome [53] or depression [54]), and/or
specific placebo-controlled RCTs. PoP could be adapted to
improve patients’ understanding of open-label placebo
interventions [35,55] and/or to educate patients about placebo
effects and mind-body interactions more broadly. It would be
interesting to examine its impact on willingness to use such
interventions. It would also be interesting to explore its use in
placebo-controlled surgery trials where there are large placebo
effects [56]. However, it would not be appropriate to use PoP
as part of participant information for trials in conditions in which
placebo effects are poorly understood or rarely seen, making it
important to consult up-to-date reviews of placebo effects before
finalizing placebo information for any specific trial.
Furthermore, before it is used in an RCT, it is important to test
for any additional effects of PoP on trial variables, specifically
the size of the placebo effect in both placebo and verum arms,
the success of blinding, and patients’ reactions to debriefing.
In this study, the person-based website led to increased
expectations of effectiveness of a placebo. Positive outcome
expectations are a key mechanism underpinning placebo effects
in pain and other conditions [31]. Therefore, if PoP were to
increase patients’ expectations of effectiveness in a
placebo-controlled RCT, this could also lead to larger placebo
effects and thus have implications for power calculations and
the efficacy of the target treatment.
The use of PoP in RCTs could also have implications for
successful blinding of patients to treatment allocation.
Qualitative studies suggest that patients typically believe if they
experience no side effects in a trial, then this means they are
receiving the placebo, whereas if they do experience side effects,
then this means they are receiving the verum intervention
[12,57]. This logic is appealing but incorrect as patients in
placebo groups regularly report benefits and adverse effects,
particularly in pain trials [5,58]. As PoP increases patients’
knowledge about the positive and adverse effects of placebos,
this could reduce patients’ confidence in a link between effects
and treatment allocation, thus helping to maintain uncertainty
and, therefore, blinding. Believing that placebos can have no
effects might also lead patients to be surprised and/or distressed
on being debriefed at the end of a trial and finding out they were
in the placebo group [10,14,15,57]. Future research could use
PoP to test whether providing more comprehensive information
about placebos at the start of a trial can improve patients’ and
investigators’ experiences of debriefing at the end of a trial.
Strengths and Limitations
Strengths of this study include the systematic approach used to
develop the person-based website, the choice of a Web-based
modality and the use of a control intervention. PoP had
previously been developed using person-based, theory-based,
and evidence-based intervention designs [28,42]. This ensured
it was engaging, persuasive, and based on current scientific
evidence about the size and mechanisms of action of placebo
effects. Compared with traditional paper-based patient
information leaflets, creating a website enabled us to provide
more detailed information in an accessible and engaging manner
using a range of formats including text, audio, and film. Other
studies of person-based digital interventions typically compare
them with usual care (ie, nondigital) [59,60]. This study
contributes a demonstration of the value of the person-based
approach to intervention development as compared with a
website based on standard written patient information.
Limitations stem from the choice of control, the sample, and
the measure of informed choice. The use of a control website
based on existing printed materials enabled a pragmatic
evaluation of the potential impact of PoP but did not allow an
evaluation of which components of the website were most
important; for example, both websites included (different) text
and images, but PoP also included audio clips and short films
and was longer than the control website. It is, therefore, possible
that the effects of PoP were because of these differences in sheer
volume of information.
Online health information is accessible to a large majority—but
not all—of the population: in 2015, 86% of UK households had
internet access and 78% of adults accessed the internet daily or
almost daily [61]. The generalizability of the study is somewhat
limited as there was a very low uptake from the initial mail out
via GP surgeries (leading to possible selection bias) and only
people with self-reported recent back pain were included. It is
not possible to compare the participants with all patients who
were invited to take part as no information could be ascertained
about the latter group. As we invited patients who had consulted
their GP with back pain as much as 3 years ago, it is possible
that many of the nonresponders were no longer seeking
treatment for back pain, and therefore, this study was not
relevant to them. The inclusion criteria do not directly map onto
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current definitions of acute or chronic back pain but were chosen
to capture a group of people for whom PoP might be of interest.
The website should have similar effects on other groups of
people with painful conditions, but this could be tested in future
studies. The final sample size fell short of the a priori sample
size calculation by 1 participant, but as almost all the results
were statistically significant, this did not seem to have an impact
on the findings.
The outcome measures were previously validated and included
an assessment of objective knowledge and an assessment of
informed choice, which is particularly relevant when considering
the potential use of the website to inform volunteers for RCTs.
However, the conceptual strength of measuring informed choice
must be balanced by an acknowledgment of the statistical
limitations of the loss of data associated with this particular
outcome measure, as it was derived (following published
guidelines) by dichotomizing 3 continuous variables. Finally,
it must be noted that the participants in this study were asked
about intentions and willingness to take part in a
placebo-controlled trial without actually being invited to take
part in a specific trial. This is a limitation for at least two
reasons. First, intentions and willingness to do something do
not always translate into actual behavior [62]. Second,
placebo-controlled trial participants receive information about
the trial treatment and procedures as well as about the placebo,
and they have to decide whether they would be willing to receive
either, not just one, of these interventions. Future studies should,
therefore, examine the use of enhanced information resources
such as the PoP website in the context of an actual
placebo-controlled trial.
Conclusions
In conclusion, the person-based website, PoP, increased
knowledge, led more participants to make an informed choice,
and enhanced positive beliefs about placebos in a sample of
adults with recent back pain recruited from primary care. It
could be used to increase levels of understanding about placebo
effects among the general public. In future, PoP could be adapted
and used to support informed consent and recruitment to
placebo-controlled clinical trials, but first, its effects on
recruitment and trial outcomes should be investigated in the
context of a placebo-controlled trial. This study provides initial
evidence suggesting that the person-based method of developing
Web-based interventions—combining extensive qualitative
research with evidence-based and theory-based methods
[42]—could be used to improve informed consent materials in
clinical research. Further work is needed to confirm its utility
in the development of materials to support the ethical conduct
of clinical research.
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